← Back

Pharma & biotech

16 covered stocks · 9 with direct model links · 12 with model news links

FBRXForte Biosciences76.99 0.00%
1 direct
▼FBRX 8-K — Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Listing Rule · Departure or Election of Directors or Officers
PFEPfizer28.78 -0.19%
2 direct1 2nd-order
▲Q3 Earnings & JOLTS Report on Midterm Voting Day
LLYEli Lilly1445.79 +1.42%
1 direct1 2nd-order
▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
NVONovo Nordisk41.41 +1.86%
2 direct
▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
AZNAstraZeneca184.81 +0.23%
1 direct1 2nd-order
▲AstraZeneca Partners With Oracle to Refine Clinical Research With AI
BIIBBiogen252.3 +0.73%
1 direct
▲Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
ZTSZoetis83.29 +0.40%
1 direct
▼Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
ABBVAbbVie294.77 +0.11%
1 direct
▲Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)
JNJJohnson & Johnson286.27 +0.97%
1 direct
▲RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
REGNRegeneron956.6 +0.57%
1 2nd-order
▼REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
MRKMerck146.49 -0.31%
1 2nd-order
▲Q3 Earnings & JOLTS Report on Midterm Voting Day
AMGNAmgen465.84 -0.26%
1 2nd-order
▼Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
BMYBristol Myers Squibb63 +1.09%
—
—
GILDGilead168.21 +0.15%
—
—
MRNAModerna224 -3.18%
—
—
VRTXVertex Pharmaceuticals538.89 -0.69%
—
—

Stock	Delayed quote	Model news links	Top-ranked story (model)
FBRX Forte Biosciences	76.99 0.00%	1 direct	▼FBRX 8-K — Completion of Acquisition or Disposition of Assets · Notice of Delisting or Failure to Satisfy a Listing Rule · Departure or Election of Directors or Officers
PFE Pfizer	28.78 -0.19%	2 direct1 2nd-order	▲Q3 Earnings & JOLTS Report on Midterm Voting Day
LLY Eli Lilly	1445.79 +1.42%	1 direct1 2nd-order	▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
NVO Novo Nordisk	41.41 +1.86%	2 direct	▲UBS portfolio manager: S&P 500 could hit 9,500 by June 2027 on AI, longevity, energy boom
AZN AstraZeneca	184.81 +0.23%	1 direct1 2nd-order	▲AstraZeneca Partners With Oracle to Refine Clinical Research With AI
BIIB Biogen	252.3 +0.73%	1 direct	▲Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience
ZTS Zoetis	83.29 +0.40%	1 direct	▼Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales
ABBV AbbVie	294.77 +0.11%	1 direct	▲Dividend Announcements: October 24-30, 2026 (Part 1 Of 2)
JNJ Johnson & Johnson	286.27 +0.97%	1 direct	▲RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
REGN Regeneron	956.6 +0.57%	1 2nd-order	▼REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
MRK Merck	146.49 -0.31%	1 2nd-order	▲Q3 Earnings & JOLTS Report on Midterm Voting Day
AMGN Amgen	465.84 -0.26%	1 2nd-order	▼Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
BMY Bristol Myers Squibb	63 +1.09%	—	—
GILD Gilead	168.21 +0.15%	—	—
MRNA Moderna	224 -3.18%	—	—
VRTX Vertex Pharmaceuticals	538.89 -0.69%	—	—

Quotes are delayed. News links are model classifications, not verified article mentions; older records without a link type are grouped as direct. Ranking uses time-decayed model scores and preset analysis windows, not observed price effects or expected returns. A window ending does not establish that the market impact has ended.

← All industries